ReviewClinical immunology (Orlando, Fla.)2013
Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application.
Review in Clinical immunology (Orlando, Fla.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 49 citations in OpenAlex.
- Longitudinal plasma proteomics identifies diagnostic and response-associated inflammatory and immune biomarkers in psoriasis following secukinumab therapy.Frontiers in immunology · 2026Article
- Comparative Analysis of the Therapeutic Effects of Fresh and Cryopreserved Human Umbilical Cord Derived Mesenchymal Stem Cells in the Treatment of Psoriasis.Stem cell reviews and reports · 2023Article
- Mast Cells and Interleukins.International journal of molecular sciences · 2022Review
- A case report of recalcitrant aphthous ulcers in two patients treated with interleukin-17 inhibitors.SAGE open medical case reports · 2021Article
- Current Developments in the Immunology of Psoriasis.The Yale journal of biology and medicine · 2020Review
- Therapeutic Effects of Synthetic Antimicrobial Peptides, TRAIL and NRP1 Blocking Peptides in Psoriatic Keratinocytes.Chonnam medical journal · 2019Review
- Tofacitinib: A New Oral Therapy for Psoriasis.Clinical drug investigation · 2018Review
- Where Does Inflammation Fit?Current cardiology reports · 2017Review
- Emerging targeted therapies for plaque psoriasis - impact of ixekizumab.Clinical, cosmetic and investigational dermatology · 2017Review
- Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab.Therapeutics and clinical risk management · 2017Review
- Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials.Dermatology and therapy · 2016Review
- Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials.Dermatology and therapy · 2016Review
- Effect of interleukin-17 on receptor-interacting protein 4 expression and keratinocyte proliferation.Experimental and therapeutic medicine · 2015Article
- Treatment of Bullous Systemic Lupus Erythematosus.Journal of immunology research · 2015Review
- Mannan induces ROS-regulated, IL-17A-dependent psoriasis arthritis-like disease in mice.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients.World journal of gastroenterology · 2014Article
- Current and potential immune therapies and vaccines in the management of psoriasis.Human vaccines & immunotherapeutics · 2014Review
- Immunotargeting in the management of psoriasis.ImmunoTargets and therapy · 2013Review
- Article
- Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.Psoriasis (Auckland, N.Z.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Psoriasis vulgaris is a chronic, immune-mediated inflammatory skin disease associated with complex genetic susceptibility. Although the hallmark of psoriasis is characterized by cutaneous inflammation and keratinocyte hyperproliferation, recent studies show that the pathologic features observed in psoriasis arises as a result of innate and adaptive immune activation in genetically prone individuals. Studies focused on the microenvironment in the skin of psoriasis lesions have revealed novel cellular and cytokine abnormalities of the immune system. One pathway important is the role of the T(H)17/IL-17 dysregulation. The recent development of biologics that target the IL-17 cytokine pathway has confirmed the importance of T(H)17 and IL-17 homeostasis in the skin and yielded potent therapies in the treatment of psoriasis, and potentially other autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.